Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases.

The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer, and in autoimmune diseases. Cell therapies have had an inarguable impact within the drug discovery and development industry but challenges have emerged. Whilst cell therapies can represent a potentially curative treatment for diseases in oncology and autoimmunity, access to such treatments has remained limited due to manufacturing constraints, scalability, side-effects, and the overall cost associated with the treatments.

Now, companies like Artiva have emerged with the intention of making cell therapies more accessible for patients suffering from autoimmune disease and cancer.

Read the full article on Drug Discovery World (free registration).